AbbVie 2012 Annual Report Download - page 104

Download and view the complete annual report

Please find page 104 of the 2012 AbbVie annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 200

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132
  • 133
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • 145
  • 146
  • 147
  • 148
  • 149
  • 150
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • 161
  • 162
  • 163
  • 164
  • 165
  • 166
  • 167
  • 168
  • 169
  • 170
  • 171
  • 172
  • 173
  • 174
  • 175
  • 176
  • 177
  • 178
  • 179
  • 180
  • 181
  • 182
  • 183
  • 184
  • 185
  • 186
  • 187
  • 188
  • 189
  • 190
  • 191
  • 192
  • 193
  • 194
  • 195
  • 196
  • 197
  • 198
  • 199
  • 200

PART III
ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
Incorporated herein by reference are ‘‘Information Concerning Director Nominees,’’ ‘‘The Board
of Directors and its Committees—Committees of the Board of Directors,’’ ‘‘Section 16(a) Beneficial
Ownership Reporting Compliance,’’ and ‘‘Procedure for Recommendation and Nomination of Directors
and Transaction of Business at Annual Meeting’’ to be included in the 2013 AbbVie Inc. Proxy
Statement. The 2013 Proxy Statement will be filed on or about March 15, 2013. Also incorporated
herein by reference is the text found under the caption, ‘‘Executive Officers of the Registrant’’ on
pages 35 through 36 hereof.
AbbVie’s code of business conduct requires all its business activities to be conducted in compliance
with laws, regulations, and ethical principles and values. All directors, officers, and employees of
AbbVie are required to read, understand, and abide by the requirements of the code of business
conduct applicable to them.
Any waiver of the code of business conduct for directors or executive officers may be made only by
AbbVie’s audit committee. AbbVie will disclose any amendment to, or waiver from, a provision of the
code of conduct for the principal executive officer, principal financial officer, principal accounting
officer or controller, or persons performing similar functions, on its website within four business days
following the date of the amendment or waiver. In addition, AbbVie will disclose any waiver from the
code of business conduct for the other executive officers and for directors on the website.
AbbVie has a chief ethics and compliance officer who reports to both the chief executive officer
and to the public policy committee. The chief ethics and compliance officer is responsible for
overseeing, administering, and monitoring AbbVie’s compliance program.
ITEM 11. EXECUTIVE COMPENSATION
The material to be included in the 2013 Proxy Statement under the headings ‘‘Director
Compensation,’’ ‘‘Executive Compensation,’’ and ‘‘Compensation Committee Report’’ is incorporated
herein by reference. The 2013 Proxy Statement will be filed on or about March 15, 2013.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
AND RELATED STOCKHOLDER MATTERS
(a) Equity Compensation Plan Information. AbbVie did not have any outstanding shares issued under
a company equity compensation plan as of December 31, 2012.
(b) Information Concerning Security Ownership. Incorporated herein by reference is the material
under the heading ‘‘Ownership of Securities—Security Ownership of Executive Officers and
Directors’’ in the 2013 Proxy Statement. The 2013 Proxy Statement will be filed on or about
March 15, 2013.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR
INDEPENDENCE
The material to be included in the 2013 Proxy Statement under the headings ‘‘The Board of
Directors and its Committees,’’ ‘‘Corporate Governance Materials,’’ ‘‘Procedures for Approval of
Related Person Transactions,’’ and ‘‘Transactions with Abbott’’ is incorporated herein by reference. The
2013 Proxy Statement will be filed on or about March 15, 2013.
ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES
The material to be included in the 2013 Proxy Statement under the headings ‘‘Audit Information—
Audit Fees and Non-Audit Fees’’ and ‘‘Audit Information—Policy on Audit Committee Pre-Approval of
Audit and Permissible Non-Audit Services of the Independent Auditor’’ is incorporated herein by
reference. The 2013 Proxy Statement will be filed on or about March 15, 2013.
98